Dhairya A. Patel

Array ( [id] => 17947102 [patent_doc_number] => 20220334121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => LIQUID BIOPSY TO DETECT CANCER EARLY AND SENSITIVELY IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 [patent_app_type] => utility [patent_app_number] => 17/586676 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910363 [patent_doc_number] => 11873333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Compositions and methods comprising SFRP2 antagonists [patent_app_type] => utility [patent_app_number] => 17/547550 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 24742 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556455 [patent_doc_number] => 20240368247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => THERAPEUTIC APPLICATIONS OF TYPE 1 INSULIN-LIKE GROWTH FACTOR (IGF-1) RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/255682 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830880 [patent_doc_number] => 20230399405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY [patent_app_type] => utility [patent_app_number] => 18/035399 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879170 [patent_doc_number] => 20240002539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => MULTISPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/035027 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -118 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578841 [patent_doc_number] => 20220135696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 17/517567 [patent_app_country] => US [patent_app_date] => 2021-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17517567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987791 [patent_doc_number] => 20240059760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => POLYPEPTIDES FOR DETECTION AND TREATMENT OF SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 18/251351 [patent_app_country] => US [patent_app_date] => 2021-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345250 [patent_doc_number] => 20240254213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => GDF15 MODULATOR FOR USE IN INHIBITION OF OCULAR TISSUE FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/034293 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18809977 [patent_doc_number] => 20230384312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => CIRCULATING MICROVESICLES EXPRESSING CARBONIC ANHYDRASE 9 FOR THE PROGNOSIS OF RENAL CELL CARCINOMA [patent_app_type] => utility [patent_app_number] => 18/249830 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754022 [patent_doc_number] => 20230357388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/028658 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314973 [patent_doc_number] => 20210404021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => METHOD, KIT, AND PROGRAM FOR DETERMINING CHARACTERISTIC OF TUMOR CELL GROUP [patent_app_type] => utility [patent_app_number] => 17/470722 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673028 [patent_doc_number] => 20230310499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => PLASMA EXCHANGE REMOVAL OF SPD-L1 [patent_app_type] => utility [patent_app_number] => 18/020515 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18020515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612411 [patent_doc_number] => 20230279143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => PROTEIN COMPRISING ANTIBODY FOR TARGETING ONCOGENIC PROTEIN OR SINGLE CHAIN FRAGMENT VARIABLE THEREOF AND CANCER CELL PENETRATING PEPTIDE, AND USE OF THE SAME [patent_app_type] => utility [patent_app_number] => 18/006387 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533950 [patent_doc_number] => 20220112559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => TARGETING TREATMENT FOR ADAM30 IN PATHOLOGICAL CELLS [patent_app_type] => utility [patent_app_number] => 17/400308 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647907 [patent_doc_number] => 20230293686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF SIRPALPHA-MEDIATED SIGNALING [patent_app_type] => utility [patent_app_number] => 18/006119 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649526 [patent_doc_number] => 20230295342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => CLINICAL METHODS FOR USE OF HER2 BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/006216 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302464 [patent_doc_number] => 12448442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Treatment of T cell lymphoma [patent_app_type] => utility [patent_app_number] => 17/381418 [patent_app_country] => US [patent_app_date] => 2021-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17375 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840179 [patent_doc_number] => 12252549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Pertuzumab plus trastuzumab fixed dose combination [patent_app_type] => utility [patent_app_number] => 17/304909 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 29 [patent_no_of_words] => 34880 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17304909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198672 [patent_doc_number] => 20210338766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS OF TREATING MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 17/243863 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376018 [patent_doc_number] => 20230151100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator [patent_app_type] => utility [patent_app_number] => 17/920442 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920442 [rel_patent_id] =>[rel_patent_doc_number] =>)